Navigation Links
Right warfarin dose determined by 3 genes
Date:3/20/2009

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are published in the scientific journal PLoS Genetics.

"We have previously studied selected genes that can affect warfarin treatment. Now that we have gone in and scanned the entire genome, we see that the two most important genes are among those we previously singled out," says Mia Wadelius, a researcher at Uppsala University, and one of the scientists behind the study.

She also says that this is the first truly large warfarin study in which all genes were reviewed at the same time. More than 1,000 warfarin patients and roughly 370,000 gene variants, covering the entire human genome, were studied.

"The adequate warfarin dosage for a patient is determined by three genes: VKORC1, CYP2C9, and CYP4F2. This is a step forward for a large group of patients, because it will be easier to determine the dosage, and the treatment will be less risky," says Mia Wadelius.

Patients vary in their sensitivity to warfarin, which makes treatment initially a risky balancing act between bleeding and blood clots. Mia Wadelius says that the variation is great among patients, sometimes up to a difference of twenty times. But now that researchers have managed to identify which genes underlie this variation, it will be possible to predict different patients' needs for warfarin more precisely, rendering treatment safer. The next step is to look for markers for bleeding.

"We will continue to look for genetic variants that influence the risk of bleeding, which can be a reaction to warfarin treatment, though a rare one. The findings of the Swedish study will be combined with those from a British study in order to attain a sufficiently robust analysis of risks of bleeding," says Mia Wadelius.


'/>"/>

Contact: Mia Wadelius
mia.wadelius@medsci.uu.se
46-018-611-4945
Uppsala University
Source:Eurekalert

Page: 1

Related medicine news :

1. Stressed-Out Moms Carry Babies on the Right
2. Bright tumors, dim prospects
3. Quality Innovators to Network in Atlanta Sept. 19-21: Learn from Those Who Got It Right
4. Right breakfast bread keeps blood sugar in check all day
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Experts Agree. Ohios Technology Investment Future Looks Bright
7. L.A. Playwright Creates an Enormous Wave with His New Book, Touch the Ocean
8. Civil Rights and Medical Leaders Call for Social Justice in Health Care
9. Flynn Pharma Acquires Rights From Pacira Pharmaceuticals to DepoDur(R), the Only Extended-Release Epidural Opioid for Post-Operative Pain, in Europe
10. New Report Says Health Courts Bureaucracies Offer Big Financial Burdens and Loss of Patient Rights
11. Federal Trade Commission Attempts To Suppress Best-Selling Authors First Amendment Rights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... By Kathleen Doheny ... (HealthDay News) -- Birth control pills containing high doses ... the risk of breast cancer in women under 50, ... oral contraceptive formulations," explained lead researcher Elisabeth Beaber, a ... in Seattle. "Some of these formulations increase breast cancer ...
(Date:8/1/2014)... Roaming the high Alps more than 5,000 years ago, ... Man" no doubt had a very tough and active lifestyle. ... the Ice Man, nicknamed Otzi, from a very modern scourge: ... "hardening of the arteries," appears to be the same today ... finds. "Our ancestors going back thousands of years ...
(Date:8/1/2014)... The European gas chromatography systems report defines ... forecast of revenue. The gas chromatography systems market in Europe ... to grow to around $247.6 million by 2018, at a ... the TOC of the European gas chromatography systems market, to ... provides a glimpse of the segmentation of gas chromatography systems ...
(Date:8/1/2014)... to a new market research report of "Thermocouples and ... (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace & Defense) ... & Forecast to 2010 - 2020", published by MarketsandMarkets, ... Billion by 2020 at a CAGR of 3.70% and ... $238.17 Million by 2020 at a CAGR of 13.81% ...
(Date:8/1/2014)... The Gerontological Society of America (GSA) ... the field of aging has chosen J. ... 2014 recipient of the Distinguished Career Contribution to ... annually to an individual whose theoretical contributions have ... or have yielded original and elegant research designs ...
Breaking Medicine News(10 mins):Health News:Some Birth Control Pills May Up Breast Cancer Risk 2Health News:Some Birth Control Pills May Up Breast Cancer Risk 3Health News:'Ice Man' Mummy May Have Been at Risk of Heart Disease 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2
... VIEW, Calif., Nov. 20 Omnicell, Inc. (Nasdaq: OMCL ) a ... company will present at the 21st Annual Piper Jaffray Healthcare Conference ... , Omnicell Speakers: Randall A. Lipps, founder, chairman, president & ... Tuesday, December 1, 2009 , Time: 1:00 p.m. EST , ...
... , NEW YORK, Nov. 20 Today, ... announce the launch of a capsule gift giving collection offered exclusively ... is inspired by and designed for St. Jude,s Children,s Research Hospital,s ... program which encourages consumers to "give thanks for the healthy kids ...
... DEL REY, Calif., Nov. 20 Heritage Provider Network, and its ... November 6, 2009, Lakeside Medical Systems, Inc., as well as all ... of the HPN family. , "We first and foremost want to ... are dedicated to maintaining the high level of care they are ...
... ... the national healthcare network, to deliver multispecialty physicians for locum tenens (temporary substitute) ... ... Healthcare is pleased to announce its agreement with VHA Inc., the national healthcare ...
... , NEW ... new market research report is available in its ... Market Review , http://www.reportlinker.com/p0164325/Imaging-Agents---A-Worldwide-Market-Review.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire ... visualization of organs within the human body. With ...
... , Carrying and Lifting Tips to Keep you Injury-free this ... travelers have a saying - " Pack your bags, then take out ... bring much more than we need on our trips. Now, even ... are charging passengers a fee for checking luggage . However, ...
Cached Medicine News:Health News:Omnicell to Present at Piper Jaffray Healthcare Conference 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 2Health News:DKNY JEANS Launches Exclusive Collection With HSN for St. Jude Children's Research Hospital's Thanks and Giving(R) Campaign 3Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 2Health News:Heritage Provider Network CEO Dr. Richard Merkin, Announces the Acquisition of Lakeside Medical Systems, Inc. 3Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 2Health News:VHA Names Jackson Healthcare as Preferred Physician Staffing Vendor 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 2Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 3Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 4Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 5Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 6Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 7Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 8Health News:Reportlinker Adds Imaging Agents - A Worldwide Market Review 9Health News:This Thanksgiving, Lug your Luggage Safely 2Health News:This Thanksgiving, Lug your Luggage Safely 3
(Date:7/31/2014)...  Cepheid (NASDAQ: CPHD ) today announced that ... invited investors to participate via webcast. ... NY Wednesday, August 13, 2014 at 9.10 a.m. ... New York, NY Thursday, September 4, 2014 ... Webcasts To access the live webcasts for these events, please ...
(Date:7/31/2014)... , July 31, 2014 Rock Creek ... that it has initiated the development of its lead ... and that it has selected Quotient Clinical, The Translational ... (UK) to run its early development programs. ... Trial Application (CTA) by the end of the third ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Cepheid to Webcast Upcoming Financial Presentations 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 2Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 3Rock Creek Pharmaceuticals Provides Update of its European Drug Development Regulatory Strategy and selects Quotient Clinical for its early development programs 4Lazarus Effect Closes $5 Million Financing 2
... SAN DIEGO, Jan. 31 TargeGen, Inc. ... multi-center Phase I/II clinical trial of,TG101348, an ... JAK2 in,patients with myeloproliferative diseases., (Logo: ... of JAK2 is implicated in the pathogenesis ...
... Mayo clinic in key role in treatment discovery, ... New York,based company Cytopia Limited (ASX: CYT) announced ... demonstrated potent activity in cells,isolated from patients with ... of diseases where there is over-production of,particular cells ...
Cached Medicine Technology:TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients 2JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: